Menu
Recruiting NCT07388394

Polypharmacy on Healthy Aging in People Living With HIV Over the Age of 75

No phase Interventional Virus-HIV

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: interview with advanced practice nurse.
Who it may be relevant to
Registry conditions: Virus-HIV. Basic parameters: from 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Describe and Evaluate the Impact of Polypharmacy on Healthy Aging in People Living With HIV Over the Age of 75 Who Are Being Treated at Nice University Hospital.

Overview

Since the advent of antiretroviral treatments, the life expectancy of people living with HIV (PLHIV) has increased significantly. In France, more than 30% of PLHIV are now over 50 years old. This population is exposed to high multimorbidity, leading to frequent polypharmacy, defined as the regular use of at least five medications. Polypharmacy also has a qualitative dimension, including potentially inappropriate prescriptions. It increases the risk of adverse effects and drug interactions and impairs quality of life. A coordinated geriatric approach is therefore essential to optimize care. Healthy aging, promoted by the WHO, aims to improve the lives of older people. In this context, a study will be conducted at the Nice University Hospital among PLHIV aged 75 and over. It will collect quantitative data, the results of which will enable us to consider, if necessary, adapting the care pathways of these patients whose needs are complex.

Interventions

  • Other interview with advanced practice nurse
    45 to 60 minutes of interview

Primary outcome measures

  • Describe polypharmacy among people living with HIV aged 75 and older. [Time frame: 15 months]
Secondary outcome measures (3)
  • Assess the most common comorbidities associated with polypharmacy in the population of PLHIV aged 75 [Time frame: 15 months]
  • Assess whether people taking multiple medications have a lower treatment adherence score than those taking fewer medications. [Time frame: 15 months]
  • Assess the level of functional independence in this age group and link it to the existence of polypharmacy. [Time frame: 15 months]

Eligibility criteria

Inclusion criteria

  • HIV-positive
  • Aged 75 or over
  • Affiliated with the social security system
  • Having expressed no objection to participating in the study

Exclusion criteria

  • Refusal to participate
  • Known severe cognitive impairment preventing the interview from being conducted
  • Patient under guardianship or conservatorship

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Other

Study locations

France · 1 center
  • CHU de NICE — Nice

Identifiers

NCT: NCT07388394 · 25-PP-19

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗